1. Home
  2. GAU vs MGTX Comparison

GAU vs MGTX Comparison

Compare GAU & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galiano Gold Inc.

GAU

Galiano Gold Inc.

HOLD

Current Price

$2.50

Market Cap

731.5M

Sector

N/A

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$8.87

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAU
MGTX
Founded
1999
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
731.5M
744.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GAU
MGTX
Price
$2.50
$8.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$3.00
$23.83
AVG Volume (30 Days)
2.8M
625.1K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$352,642,000.00
$27,417,000.00
Revenue This Year
$82.50
N/A
Revenue Next Year
$57.71
$619.95
P/E Ratio
N/A
N/A
Revenue Growth
111.43
96.83
52 Week Low
$1.00
$4.55
52 Week High
$3.12
$9.73

Technical Indicators

Market Signals
Indicator
GAU
MGTX
Relative Strength Index (RSI) 56.09 59.23
Support Level $2.29 $8.25
Resistance Level $2.64 $9.50
Average True Range (ATR) 0.13 0.52
MACD 0.03 0.10
Stochastic Oscillator 70.10 67.86

Price Performance

Historical Comparison
GAU
MGTX

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Share on Social Networks: